Fortem Neurosciences Overview
- Year Founded
-
2016
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
Fortem Neurosciences General Information
Description
Developer of novel small-molecule drugs intended to eliminate Alzheimer's, Dementia, and other brain diseases. The company focuses on the development of molecular drugs that function as regulators of gene expression and have shown significant activity in animal models of cognitive decline, allowing scientists and medical professionals to find an exact cure for long-lasting diseases.
Contact Information
Website
www.fortemneurosciences.comCorporate Office
- 12100 Wilshire Boulevard
- Suite 800
- Los Angeles, CA 90025
- United States
Corporate Office
- 12100 Wilshire Boulevard
- Suite 800
- Los Angeles, CA 90025
- United States
Fortem Neurosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Secondary Transaction - Private | 01-Apr-2024 | Completed | Startup | |||
| 1. Early Stage VC (Series A) | 12-May-2016 | Completed | Startup |
Fortem Neurosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Fortem Neurosciences Patents
Fortem Neurosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023408901-A1 | Methods and compositions for the treatment of parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, and learning disorders | Pending | 20-Dec-2022 | ||
| EP-4637745-A1 | Methods and compositions for the treatment of parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, and learning disorders | Pending | 20-Dec-2022 | ||
| US-20260207585-A1 | Methods and compositions for the treatment of parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, and learning disorders | Pending | 20-Dec-2022 | ||
| WO-2024137659-A1 | Methods and compositions for the treatment of parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, and learning disorders | Inactive | 20-Dec-2022 | ||
| AU-2021320639-A1 | Compositions and methods for treating alzheimer's disease | Pending | 03-Aug-2020 | A61K31/548 |
Fortem Neurosciences FAQs
-
When was Fortem Neurosciences founded?
Fortem Neurosciences was founded in 2016.
-
Where is Fortem Neurosciences headquartered?
Fortem Neurosciences is headquartered in Los Angeles, CA.
-
What industry is Fortem Neurosciences in?
Fortem Neurosciences’s primary industry is Drug Discovery.
-
Is Fortem Neurosciences a private or public company?
Fortem Neurosciences is a Private company.
-
What is Fortem Neurosciences’s current revenue?
The current revenue for Fortem Neurosciences is .
-
How much funding has Fortem Neurosciences raised over time?
Fortem Neurosciences has raised $2M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process